[HTML][HTML] Circulating tumor nucleic acids: biology, release mechanisms, and clinical relevance
Background Despite advances in early detection and therapies, cancer is still one of the
most common causes of death worldwide. Since each tumor is unique, there is a need to …
most common causes of death worldwide. Since each tumor is unique, there is a need to …
[HTML][HTML] Liquid biopsy for advanced NSCLC: a consensus statement from the international association for the study of lung cancer
Although precision medicine has had a mixed impact on the clinical management of patients
with advanced-stage cancer overall, for NSCLC, and more specifically for lung …
with advanced-stage cancer overall, for NSCLC, and more specifically for lung …
[HTML][HTML] Trastuzumab Deruxtecan in HER2-Mutant Non–Small-Cell Lung Cancer
Background Human epidermal growth factor receptor 2 (HER2)–targeted therapies have not
been approved for patients with non–small-cell lung cancer (NSCLC). The efficacy and …
been approved for patients with non–small-cell lung cancer (NSCLC). The efficacy and …
Practical considerations for the use of circulating tumor DNA in the treatment of patients with cancer: a narrative review
Importance Personalized medicine based on tumor profiling and identification of actionable
genomic alterations is pivotal in cancer management. Although tissue biopsy is still …
genomic alterations is pivotal in cancer management. Although tissue biopsy is still …
[HTML][HTML] A clinician's handbook for using ctDNA throughout the patient journey
SO Hasenleithner, MR Speicher - Molecular cancer, 2022 - Springer
Background The promise of precision cancer medicine presently centers around the
genomic sequence of a patient's tumor being translated into timely, actionable information to …
genomic sequence of a patient's tumor being translated into timely, actionable information to …
[HTML][HTML] Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges
M Garcia-Pardo, M Makarem, JJN Li, D Kelly… - British Journal of …, 2022 - nature.com
In the current era of precision medicine, the identification of genomic alterations has
revolutionised the management of patients with solid tumours. Recent advances in the …
revolutionised the management of patients with solid tumours. Recent advances in the …
[HTML][HTML] Liquid biopsy in prostate cancer management—Current challenges and future perspectives
Simple Summary Prostate cancer (PCa) is a widespread malignancy, representing the
second leading cause of cancer-related death in men. In the last years, liquid biopsy has …
second leading cause of cancer-related death in men. In the last years, liquid biopsy has …
ctDNA as a cancer biomarker: A broad overview
LS Pessoa, M Heringer, VP Ferrer - Critical reviews in oncology …, 2020 - Elsevier
Circulating tumor DNA (ctDNA) in fluids has gained attention because ctDNA seems to
identify tumor-specific abnormalities, which could be used for diagnosis, follow-up of …
identify tumor-specific abnormalities, which could be used for diagnosis, follow-up of …
[HTML][HTML] Tailored point-of-care biosensors for liquid biopsy in the field of oncology
In the field of cancer detection, technologies to analyze tumors using biomarkers circulating
in fluids such as blood have developed rapidly based on liquid biopsy. A proactive approach …
in fluids such as blood have developed rapidly based on liquid biopsy. A proactive approach …
Beyond EGFR, ALK and ROS1: current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma
G Lamberti, E Andrini, M Sisi, A Rizzo, C Parisi… - Critical reviews in …, 2020 - Elsevier
Lung cancer is the leading cause of cancer death worldwide. In the past decade EGFR, ALK
and ROS1 TKIs lead to an unprecedented survival improvement of oncogene-addicted …
and ROS1 TKIs lead to an unprecedented survival improvement of oncogene-addicted …